{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n CHRM3‐AS2 is a long non‐coding RNA that has recently emerged as a noteworthy regulator in cancer. In ovarian carcinoma, CHRM3‐AS2 was identified as part of a five–lncRNA immune‐associated signature with independent prognostic value. Its differential expression correlates with immune cell infiltration and the activation of pathways such as hedgehog, Wnt signaling, cytokine receptor interaction, antigen processing, and T cell receptor signaling, suggesting a role in modulating the tumor–immune microenvironment."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n In glioma, CHRM3‐AS2 is up‐regulated and predominantly localized in the cytoplasm. Functional studies indicate that silencing CHRM3‐AS2 impairs cell viability, colony formation, migration, and invasion while promoting apoptosis. Mechanistically, CHRM3‐AS2 acts via the miR‐370-5p/KLF4 axis, where its suppression disrupts this regulatory cascade and contributes to the inhibition of malignant progression."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": "\n "}]}, {"type": "t", "text": "\n "}, {"type": "p", "children": [{"type": "t", "text": "\n Collectively, these findings suggest that CHRM3‐AS2 may serve as both a prognostic biomarker and a potential therapeutic target in cancers where it modulates tumor progression and the immune response.\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Yan Li, Fan-Fan Huo, Ying-Ying Wen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Screening and Identification of an Immune-Associated lncRNA Prognostic Signature in Ovarian Carcinoma: Evidence from Bioinformatic Analysis."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Biomed Res Int (2021)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1155/2021/6680036"}], "href": "https://doi.org/10.1155/2021/6680036"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "33997040"}], "href": "https://pubmed.ncbi.nlm.nih.gov/33997040"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Dong Wang, Qiang Chen, Jun Liu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Silencing of lncRNA CHRM3-AS2 Expression Exerts Anti-Tumour Effects Against Glioma "}, {"type": "a", "children": [{"type": "t", "text": "i"}], "href": "i"}, {"type": "t", "text": "via"}, {"type": "a", "children": [{"type": "t", "text": "/i"}], "href": "/i"}, {"type": "t", "text": " Targeting microRNA-370-5p/KLF4."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Front Oncol (2022)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3389/fonc.2022.856381"}], "href": "https://doi.org/10.3389/fonc.2022.856381"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "35359381"}], "href": "https://pubmed.ncbi.nlm.nih.gov/35359381"}]}]}]}